Tabatha Truelove, APRN
Psychiatric/Mental Health · Wagoner, OKNPI 1164074472
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,207 of the $4,044 with a category attached, or 79.3%. 12 manufacturers reported payments, led by Johnson & Johnson at 47.7% of the total. 2025 is the largest year on record at $2,709, 4.5 times the $608 reported in 2021.
Across 143 payments — averaging $28.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$462
- Alkermes, Inc.$394
- Teva Pharmaceuticals USA, Inc.$338
- Vanda Pharmaceuticals Inc.$247
- E.r. Squibb & Sons, L.L.C.$231
- plus $442 from 6 others
What the payments were for
- Travel & lodging$73118%
- Food & beverage$3,20779%
- Education$1063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 43 | $1,930 |
| AbbVie | 30 | $462 |
| Alkermes, Inc. | 14 | $394 |
| Teva Pharmaceuticals USA, Inc. | 9 | $338 |
| Vanda Pharmaceuticals Inc. | 16 | $247 |
| E.r. Squibb & Sons, L.L.C. | 7 | $231 |
| Otsuka America Pharmaceutical, Inc. | 13 | $230 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Neurocrine Biosciences, Inc. | 3 | $71 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Indivior Inc. | 1 | $14 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$1,222
- LYBALVI$423
- INVEGA SUSTENNA$234
- INVEGA TRINZA$124
- COBENFY$122
- UZEDY$122
- VRAYLAR$117
How this compares
$4,044 in reported general payments places this provider in the 75th percentile of 231 psychiatric/mental health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 11 | $15,764 |
| OzempicSemaglutide | 11 | $11,808 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $8,994 |
| Lisdexamfetamine Dimesylate | 11 | $2,817 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $1,232 |
| Gabapentin | 66 | $1,051 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 30 | $969 |
| Fluvoxamine Maleate | 19 | $943 |
| Ziprasidone Hcl | 16 | $833 |
| Olanzapine | 41 | $822 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 52 | $798 |
| Buspirone Hcl | 57 | $723 |
| Quetiapine Fumarate | 29 | $670 |
| Bupropion XlBupropion Hcl | 37 | $651 |
| Lamotrigine | 38 | $558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $462 | $15,76411 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $72 | $8,99421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 231 psychiatric/mental health providers in Oklahoma.
Other psychiatric/mental health in Wagoner
- Meryl AaronEdmond$23K
- Fernanda CooleyTulsa$16K
- Amy BoggsNorman$15K
- Amber BrownEdmond$15K
- Sylvie MawohOklahoma City$14K
- Nicole HolzerNorman$12K
- Pramila TraxlerTulsa$12K
- Sasha LounmalaMuskogee$10K
- Sabrina ConleyTulsa$10K
- Laura HallNorman$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.